Effect of vaccines on bacterial meningitis worldwide (Q38058959)

27 August 2017

title

Effect of vaccines on bacterial meningitis worldwide (English)

1 reference

27 August 2017

1 reference

1 reference

Katherine L O'Brien

2

0 references

Brian Greenwood

series ordinal

3

object named as

Brian Greenwood

1 reference

27 August 2017

Diederik van de Beek

4

0 references

author name string

Peter B McIntyre

series ordinal

1

1 reference

27 August 2017

language of work or name

English

0 references

publication date

1 November 2012

1 reference

27 August 2017

1 reference

27 August 2017

volume

380

1 reference

27 August 2017

issue

9854

1 reference

27 August 2017

page(s)

1703-1711

1 reference

Global and regional risk of disabling sequelae from bacterial meningitis: a systematic review and meta-analysis

27 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2812%2961187-8

7 January 2021

Bacterial meningitis in the United States, 1986: report of a multistate surveillance study. The Bacterial Meningitis Study Group.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2812%2961187-8

7 January 2021

The changing epidemiology of bacterial meningitis and invasive non-meningitic bacterial disease in scotland during the period 1983-99

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2812%2961187-8

7 January 2021

Increased incidence of childhood bacterial meningitis. A 25-year study in a defined population in Sweden

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2812%2961187-8

7 January 2021

Bacterial meningitis in the United States in 1995. Active Surveillance Team

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2812%2961187-8

7 January 2021

Editorial: 100 years of epidemic meningitis in West Africa - has anything changed?

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2812%2961187-8

7 January 2021

Bacteremia among children admitted to a rural hospital in Kenya

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2812%2961187-8

7 January 2021

Streptococcus suis: an emerging human pathogen

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2812%2961187-8

7 January 2021

Global epidemiology of meningococcal disease.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2812%2961187-8

7 January 2021

Epidemic meningitis, meningococcaemia, and Neisseria meningitidis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2812%2961187-8

7 January 2021

Prevention of Haemophilus influenzae type b disease: past success and future challenges

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2812%2961187-8

7 January 2021

Epidemiological differences among pneumococcal serotypes

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2812%2961187-8

7 January 2021

African meningitis belt pneumococcal disease epidemiology indicates a need for an effective serotype 1 containing vaccine, including for older children and adults

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2812%2961187-8

7 January 2021

Temporal trends in invasive pneumococcal disease and pneumococcal serotypes over 7 decades

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2812%2961187-8

7 January 2021

The effect of HIV infection on paediatric bacterial meningitis in Blantyre, Malawi

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2812%2961187-8

7 January 2021

Invasive pneumococcal infections in children with sickle cell disease in the era of penicillin prophylaxis, antibiotic resistance, and 23-valent pneumococcal polysaccharide vaccination.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2812%2961187-8

7 January 2021

The diagnosis and management of acute bacterial meningitis in resource-poor settings

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2812%2961187-8

7 January 2021

Burden of disease caused by Streptococcus pneumoniae in children younger than 5 years: global estimates

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2812%2961187-8

7 January 2021

Burden of disease caused by Haemophilus influenzae type b in children younger than 5 years: global estimates

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2812%2961187-8

7 January 2021

The changing and dynamic epidemiology of meningococcal disease

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2812%2961187-8

7 January 2021

Global, regional, and national causes of child mortality in 2008: a systematic analysis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2812%2961187-8

7 January 2021

Streptococcus pneumoniae in western Europe: serotype distribution and incidence in children less than 2 years old.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2812%2961187-8

7 January 2021

Bacterial meningitis in Burkina Faso: surveillance using field-based polymerase chain reaction testing

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2812%2961187-8

7 January 2021

Incidences of vaccine-preventable Haemophilus influenzae type b pneumonia and meningitis in Indonesian children: hamlet-randomised vaccine-probe trial

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2812%2961187-8

7 January 2021

Haemophilus influenzae type b disease in the western region of The Gambia: background surveillance for a vaccine efficacy trial

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2812%2961187-8

7 January 2021

Severity and frequency of sequelae of bacterial meningitis in Alaska Native infants. Correlation with a scoring system for severity of sequelae

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2812%2961187-8

7 January 2021

Haemophilus influenzae type b conjugate vaccines

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2812%2961187-8

7 January 2021

Mechanisms of avoidance of host immunity by Neisseria meningitidis and its effect on vaccine development

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2812%2961187-8

7 January 2021

Efficacy of pneumococcal vaccination in children younger than 24 months: a meta-analysis.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2812%2961187-8

7 January 2021

Host genetic susceptibility to pneumococcal and meningococcal disease: a systematic review and meta-analysis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2812%2961187-8

7 January 2021

Polysaccharide vaccines for preventing serogroup A meningococcal meningitis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2812%2961187-8

7 January 2021

Vaccines for preventing pneumococcal infection in adults

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2812%2961187-8

7 January 2021

Antibody responses of three Haemophilus influenzae type b conjugate vaccines after one, two and three doses in Filipino children

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2812%2961187-8

7 January 2021

Establishment of a new human pneumococcal standard reference serum, 007sp

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2812%2961187-8

7 January 2021

The epidemiology of meningococcal disease and the impact of vaccines

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2812%2961187-8

7 January 2021

Immunogenicity and safety of a meningococcal A conjugate vaccine in Africans

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2812%2961187-8

7 January 2021

A randomized, prospective field trial of a conjugate vaccine in the protection of infants and young children against invasive Haemophilus influenzae type b disease.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2812%2961187-8

7 January 2021

Limited efficacy of a Haemophilus influenzae type b conjugate vaccine in Alaska Native infants. The Alaska H. influenzae Vaccine Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2812%2961187-8

7 January 2021

The efficacy in Navajo infants of a conjugate vaccine consisting of Haemophilus influenzae type b polysaccharide and Neisseria meningitidis outer-membrane protein complex

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2812%2961187-8

7 January 2021

Efficacy, safety and immunogenicity of heptavalent pneumococcal conjugate vaccine in children. Northern California Kaiser Permanente Vaccine Study Center Group

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2812%2961187-8

7 January 2021

Efficacy and safety of seven-valent conjugate pneumococcal vaccine in American Indian children: group randomised trial

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2812%2961187-8

7 January 2021

A trial of a 9-valent pneumococcal conjugate vaccine in children with and those without HIV infection

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2812%2961187-8

7 January 2021

Efficacy of nine-valent pneumococcal conjugate vaccine against pneumonia and invasive pneumococcal disease in The Gambia: randomised, double-blind, placebo-controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2812%2961187-8

7 January 2021

Haemophilus influenzae type b conjugate vaccine use and effectiveness

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2812%2961187-8

7 January 2021

Bacterial meningitis in the United States, 1998-2007.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2812%2961187-8

7 January 2021

Host and environmental factors associated with Hib in England, 1998-2002.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2812%2961187-8

7 January 2021

Fall in Haemophilus influenzae serotype b (Hib) disease following implementation of a booster campaign

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2812%2961187-8

7 January 2021

The Alaska Haemophilus influenzae type b experience: lessons in controlling a vaccine-preventable disease

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2812%2961187-8

7 January 2021

Herd immunity and serotype replacement 4 years after seven-valent pneumococcal conjugate vaccination in England and Wales: an observational cohort study

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2812%2961187-8

7 January 2021

Meningococcal C conjugate vaccine: the experience in England and Wales

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2812%2961187-8

7 January 2021

Is a single dose of meningococcal serogroup C conjugate vaccine sufficient for protection? experience from the Netherlands

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2812%2961187-8

7 January 2021

Fast tracking the vaccine licensure process to control an epidemic of serogroup B meningococcal disease in New Zealand

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2812%2961187-8

7 January 2021

Use of an observational cohort study to estimate the effectiveness of the New Zealand group B meningococcal vaccine in children aged under 5 years

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2812%2961187-8

7 January 2021

Haemophilus influenzae type b vaccine impact in resource-poor settings in Asia and Africa

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2812%2961187-8

7 January 2021

Invasive disease due to Haemophilus influenzae serotype b ten years after routine vaccination, South Africa, 2003-2009.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2812%2961187-8

7 January 2021

Elimination of Haemophilus influenzae type b (Hib) disease from The Gambia after the introduction of routine immunisation with a Hib conjugate vaccine: a prospective study

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2812%2961187-8

7 January 2021

Re-emergence of Haemophilus influenzae type b (Hib) disease in The Gambia following successful elimination with conjugate Hib vaccine

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2812%2961187-8

7 January 2021

Report on invasive disease and meningitis due to Haemophilus influenzae and Streptococcus pneumonia from the Network for Surveillance of Pneumococcal Disease in the East African Region

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2812%2961187-8

7 January 2021

Serogroup A meningococcal conjugate vaccination in Burkina Faso: analysis of national surveillance data

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2812%2961187-8

7 January 2021

Invasive Haemophilus influenzae disease in Alaskan residents aged 10 years and older before and after infant vaccination programs

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2812%2961187-8

7 January 2021

Changing epidemiology of invasive Haemophilus influenzae in Ontario, Canada: evidence for herd effects and strain replacement due to Hib vaccination

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2812%2961187-8

7 January 2021

No evidence for Haemophilus influenzae serotype replacement in Europe after introduction of the Hib conjugate vaccine.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2812%2961187-8

7 January 2021

Invasive Haemophilus influenzae disease in Utah children: an 11-year population-based study in the era of conjugate vaccine

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2812%2961187-8

7 January 2021

Haemophilus influenzae meningitis 5 years after introduction of the Haemophilus influenzae type b conjugate vaccine in Brazil

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2812%2961187-8

7 January 2021

Epidemiology of Haemophilus influenzae serotype a, North American Arctic, 2000-2005.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2812%2961187-8

7 January 2021

Serotype replacement in disease after pneumococcal vaccination

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2812%2961187-8

7 January 2021

Effect of pneumococcal conjugate vaccination on serotype-specific carriage and invasive disease in England: a cross-sectional study

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2812%2961187-8

7 January 2021

Pneumococcal conjugate vaccine given shortly after birth stimulates effective antibody concentrations and primes immunological memory for sustained infant protection

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2812%2961187-8

7 January 2021

Comparing pneumococcal conjugate vaccine schedules based on 3 and 2 primary doses: systematic review and meta-analysis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2812%2961187-8

7 January 2021

Maintenance of immune response throughout childhood following serogroup C meningococcal conjugate vaccination in early childhood.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2812%2961187-8

7 January 2021

Immunoglobulin deficiency in children with Hib vaccine failure

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2812%2961187-8

7 January 2021

Functional T-cell deficiency in adolescents who experience serogroup C meningococcal disease despite receiving the meningococcal serogroup C conjugate vaccine.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2812%2961187-8

7 January 2021

Invasive pneumococcal infections among vaccinated children in the United States

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2812%2961187-8

7 January 2021

Immunogenicity and tolerability of recombinant serogroup B meningococcal vaccine administered with or without routine infant vaccinations according to different immunization schedules: a randomized controlled trial.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2812%2961187-8

7 January 2021

Immunogenicity and tolerability of a multicomponent meningococcal serogroup B (4CMenB) vaccine in healthy adolescents in Chile: a phase 2b/3 randomised, observer-blind, placebo-controlled study

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2812%2961187-8

7 January 2021

Issues and challenges in the development of pneumococcal protein vaccines

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2812%2961187-8

7 January 2021

10.1016/S0140-6736(12)61187-8

Identifiers

DOI

1 reference

27 August 2017

1 reference